The structure of the dopamine D 3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology
The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D 3 receptor (D 3 R). Here, we report the cryo–electron microscopy structure of cariprazine bound to D 3 R, establishing a framework for understanding ligand recognition in this receptor. We further determine structures of D 3 R in complex with a series of cariprazine derivatives spanning inverse agonists to high-efficacy partial agonists. Integration of structural data with pharmacological profiling and molecular dynamics simulations reveals how subtle chemical modifications translate into distinct functional outcomes. Determinants distinguishing agonism from inverse agonism are well defined, whereas differences among partial agonists arise from small positional shifts of the ligand within the orthosteric binding site. In contrast, the extended binding site primarily modulates ligand stability, affinity, and receptor selectivity. These findings establish a mechanistic link between bitopic ligand architecture and receptor activation, providing a “ligand-centric” view of D 3 R signaling. Leveraging these principles, we designed and validated cariprazine derivatives with enhanced D 3 /D 2 selectivity and partial agonist activity. Together, this work provides a structural and pharmacological blueprint for the rational design of D 3 R-targeting ligands with tailored efficacy and therapeutic profiles.
Authors
- Keshet Shavit (ORCID: https://orcid.org/0000-0002-1343-2481)
- Attila Egyed (ORCID: https://orcid.org/0000-0001-8463-4219)
- J. Robert Lane (ORCID: https://orcid.org/0000-0002-7361-7875)
- György M. Keserű (ORCID: https://orcid.org/0000-0003-1039-7809)
- Moran Shalev-Benami (ORCID: https://orcid.org/0000-0001-6902-1924)
- Julie Sanchez (ORCID: https://orcid.org/0000-0002-5765-4342)
- Meritxell Canals (ORCID: https://orcid.org/0000-0002-7942-5006)
- Amy Hauck Newman (ORCID: https://orcid.org/0000-0001-9065-4072)
- Dénes Szepesi Kovács
- Supriya A. Gaitonde
- Caleb D. Vogt (ORCID: https://orcid.org/0000-0003-2224-1959)
- Michel Bouvier (ORCID: https://orcid.org/0000-0003-1128-0100)
- Dóra Kiss (ORCID: https://orcid.org/0000-0002-6664-3872)
- Jacqueline Glenn
- Eliane Yardeni (ORCID: https://orcid.org/0009-0007-3898-5035)
Institutions
- National Institute on Drug Abuse (US)
- University of Nottingham (GB)
- Institute for Research in Immunology and Cancer (CA)
- National Research, Development and Innovation Office (HU)
- Queen's Medical Centre (GB)
- National Center for Epidemiology (HU)
- Weizmann Institute of Science (IL)
- Université de Montréal (CA)
- University of Birmingham (GB)
- HUN-REN Research Centre for Natural Sciences (HU)
Publication Details
- Journal
- Science Advances
- Published
- 2026-08-28
- DOI
- https://doi.org/10.1126/sciadv.aef7411
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Nottingham
- Magyar Tudományos Akadémia
- Canadian Institutes of Health Research
- Biotechnology and Biological Sciences Research Council
- European Research Council
- Intramural Research Program